[Intravenous and oral treatment with amantadine sulfate in Parkinson disease].

Abstract

The rapid efficacy of amantadine on akinesia and rigidity in Parkinson's disease is generally known. The duration of this therapeutic result is however controversial. Some authors have reported a loss of efficacy after only a few weeks of therapy. The success of a short-term parenteral and subsequently oral long-term treatment with amantadine sulphate in 8 Parkinsonian patients was tested by means of clinical and neuropsychological examinations and by monitoring the serum concentration over the course of half a year. A ten-day intravenous treatment with amantadine sulphate (200 mg daily) led to a significant improvement in the clinical and psychological test results. This attained improvement could be maintained for 6 months with oral therapy consisting of 600 mg amantadine sulphate. There were strong interindividual variations in serum concentration.

• Authors: M Brenner, A Haass, P Jacobi, K Schimrigk
• Journal: Der Nervenarzt (Nervenarzt) Vol. 59 Issue 3 Pg. 180-4 (Mar 1988) ISSN: 0028-2804 [Print] Germany
• Vernacular Title: Intravenöse und orale Behandlung mit Amantadinsulfat bei der Parkinsonkrankheit.
• PMID: 3374720 (Publication Type: English Abstract, Journal Article)

Chemical References

• Amantadine

Topics

• Administration, Oral
• Amantadine (administration & dosage, pharmacokinetics)
• Female
• Humans
• Infusions, Intravenous
• Male
• Middle Aged
• Neuropsychological Tests
• Parkinson Disease (blood, drug therapy)